ITMI960311A0 - - Google Patents

Info

Publication number
ITMI960311A0
ITMI960311A0 ITMI960311A ITMI960311A ITMI960311A0 IT MI960311 A0 ITMI960311 A0 IT MI960311A0 IT MI960311 A ITMI960311 A IT MI960311A IT MI960311 A ITMI960311 A IT MI960311A IT MI960311 A0 ITMI960311 A0 IT MI960311A0
Authority
IT
Italy
Application number
ITMI960311A
Other languages
Italian (it)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ITMI960311A0 publication Critical patent/ITMI960311A0/it
Priority to IT96MI000311A priority Critical patent/IT1282650B1/it
Priority to US08/799,313 priority patent/US5780057A/en
Priority to ES97102567T priority patent/ES2219709T3/es
Priority to EP03078109A priority patent/EP1382331B1/en
Priority to PT97102567T priority patent/PT795324E/pt
Priority to NZ314265A priority patent/NZ314265A/en
Priority to ES03078109T priority patent/ES2376199T3/es
Priority to EP97102567A priority patent/EP0795324B1/en
Priority to DK97102567T priority patent/DK0795324T3/da
Priority to DE69728710T priority patent/DE69728710T2/de
Priority to AT03078109T priority patent/ATE530173T1/de
Priority to AU14776/97A priority patent/AU719170B2/en
Priority to AT97102567T priority patent/ATE264670T1/de
Priority to CA002197941A priority patent/CA2197941C/en
Priority to JP03491897A priority patent/JP3251190B2/ja
Publication of ITMI960311A1 publication Critical patent/ITMI960311A1/it
Application granted granted Critical
Publication of IT1282650B1 publication Critical patent/IT1282650B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
IT96MI000311A 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici IT1282650B1 (it)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US08/799,313 US5780057A (en) 1996-02-19 1997-02-14 Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
DK97102567T DK0795324T3 (da) 1996-02-19 1997-02-18 En farmaceutisk tablet kendetegnet ved, at den udviser stor volumenforögelse, når den kommer i kontakt med biologiske væsker
DE69728710T DE69728710T2 (de) 1996-02-19 1997-02-18 Eine pharmazeutische Tablette charakterisiert durch hohen Volumenzuwachs bei Kontakt mit biologischen Flüssigkeiten
PT97102567T PT795324E (pt) 1996-02-19 1997-02-18 Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos
NZ314265A NZ314265A (en) 1996-02-19 1997-02-18 Multilayered compressed tablet for selective release of medicaments at controlled rates having one layer that increases at least 50% by volume on contact with gastric juices
ES03078109T ES2376199T3 (es) 1996-02-19 1997-02-18 Un comprimido farmacéutico caracterizado por mostrar un incremento de volumen cuando entra en contacto con fluidos biológicos.
EP97102567A EP0795324B1 (en) 1996-02-19 1997-02-18 A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids
ES97102567T ES2219709T3 (es) 1996-02-19 1997-02-18 Un comprimido farmaceutico caracterizado porque presenta un gran aumento de volumen cuando entra en contacto con fluidos biologicos.
EP03078109A EP1382331B1 (en) 1996-02-19 1997-02-18 A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids
AT03078109T ATE530173T1 (de) 1996-02-19 1997-02-18 Eine pharmazeutische tablette charakterisiert durch hohen volumenzuwachs bei kontakt mit biologischen flüssigkeiten
AU14776/97A AU719170B2 (en) 1996-02-19 1997-02-18 Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
AT97102567T ATE264670T1 (de) 1996-02-19 1997-02-18 Eine pharmazeutische tablette charakterisiert durch hohen volumenzuwachs bei kontakt mit biologischen flüssigkeiten
CA002197941A CA2197941C (en) 1996-02-19 1997-02-19 A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
JP03491897A JP3251190B2 (ja) 1996-02-19 1997-02-19 体液と接触することにより容積が高度に増加する薬学的圧縮錠剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Publications (3)

Publication Number Publication Date
ITMI960311A0 true ITMI960311A0 (en:Method) 1996-02-19
ITMI960311A1 ITMI960311A1 (it) 1997-08-19
IT1282650B1 IT1282650B1 (it) 1998-03-31

Family

ID=11373320

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Country Status (12)

Country Link
US (1) US5780057A (en:Method)
EP (2) EP1382331B1 (en:Method)
JP (1) JP3251190B2 (en:Method)
AT (2) ATE264670T1 (en:Method)
AU (1) AU719170B2 (en:Method)
CA (1) CA2197941C (en:Method)
DE (1) DE69728710T2 (en:Method)
DK (1) DK0795324T3 (en:Method)
ES (2) ES2219709T3 (en:Method)
IT (1) IT1282650B1 (en:Method)
NZ (1) NZ314265A (en:Method)
PT (1) PT795324E (en:Method)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
IN186245B (en:Method) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
PT991415E (pt) * 1997-12-22 2003-06-30 Schering Corp Formas de dosagem solidas de ribavirina administraveis por via oral e processo para a sua producao
AU755616B2 (en) * 1998-06-05 2002-12-19 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
IL141339A0 (en) * 1998-09-25 2002-03-10 Delsys Pharmaceutical Corp Liquid pharmaceutical for oral delivery
DE69940557D1 (de) 1998-12-11 2009-04-23 Nostrum Pharmaceuticals Inc Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
MY121470A (en) * 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
FR2797185B1 (fr) * 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
HUP0301465A3 (en) * 2000-06-23 2006-07-28 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
EP1339395A2 (en) 2000-11-28 2003-09-03 Fmc Corporation Edible pga (propylene glycol alginate) coating composition
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
JP2004513975A (ja) * 2000-12-05 2004-05-13 マクグレゴール　アレキサンダー 作用物質の制御放出のための静水圧デリバリシステム
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
US8268333B2 (en) * 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
DE10120092B4 (de) * 2001-04-25 2008-03-20 Lts Lohmann Therapie-Systeme Ag Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
IL159812A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
AU2002340470A1 (en) 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
WO2003042136A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
JP4221299B2 (ja) * 2001-12-21 2009-02-12 ビーオパルトナーズ ゲーエムベーハー フィルム錠剤製造用リバビリン顆粒
KR20030056474A (ko) * 2001-12-28 2003-07-04 한국유나이티드제약 주식회사 카르비도파/레보도파 서방정의 조성물과 그의 제조방법
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
CN1630513A (zh) * 2002-02-04 2005-06-22 兰贝克赛实验室有限公司 流体动力平衡的以两相释放的口服药物输递系统
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
CA2499550C (en) 2002-09-20 2013-10-15 Alpharma, Inc. Sequestering subunit and related compositions and methods
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
WO2004041255A1 (en) * 2002-10-31 2004-05-21 Alza Corporation Dosage form providing ascending release of liquid formulation
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
WO2005058319A1 (en) * 2003-12-16 2005-06-30 Cnsbio Pty Ltd Methods and compositions
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
JPWO2005084703A1 (ja) * 2004-03-09 2007-11-29 株式会社Ｎｒｌファーマ 徐放性の口腔用組成物
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
AU2005295482B2 (en) * 2004-10-15 2011-03-31 Supernus Pharmaceuticals Inc. Less abusable pharmaceutical preparations
EP1830791B1 (en) * 2004-11-19 2014-09-10 GlaxoSmithKline LLC Pharmaceutical product
EP1830886B1 (en) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
EA200800162A1 (ru) * 2005-06-29 2008-06-30 Панацея Биотек Лтд. Новые фармацевтические композиции с замедленным высвобождением и способы их получения
EA014739B1 (ru) * 2005-09-09 2011-02-28 Лабофарм Инк. Композиция тразодона для введения один раз в день
US8795723B2 (en) * 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
US8187633B2 (en) 2005-11-03 2012-05-29 Sun Pharma Advanced Research Company Limited Controlled release coated tablets having prolonged gastric retention
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
KR100752417B1 (ko) * 2006-02-14 2007-08-28 대원제약주식회사 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
EP2021005A4 (en) * 2006-05-03 2009-11-25 Cnsbio Pty Ltd METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
ES2636657T3 (es) 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
ES2547226T5 (es) * 2006-08-30 2020-06-12 Jagotec Ag Formulaciones de dosificación oral de liberación controlada que comprenden un núcleo y una o más capas de barrera
WO2008039193A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
EP2066303B1 (en) * 2006-09-26 2016-05-04 Plensat, LLC System for treatment of eating disorders
CA2664641A1 (en) 2006-09-26 2008-04-10 Astellas Pharma, Inc. Controlled release dosage form of tacrolimus
EP1935411A1 (en) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
CA2674039A1 (en) 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
AT505225A1 (de) * 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090317465A1 (en) * 2008-06-16 2009-12-24 Appian Labs, Llc Composition and method of preparation of release systems for constant (zero-order) release of active agents
JP2012500221A (ja) * 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
MX2011003749A (es) * 2008-10-08 2011-09-01 Bioplus Life Sciences Pvt Ltd Sistema para suministrar medicamentos de liberacion sostenida.
WO2010048478A2 (en) * 2008-10-23 2010-04-29 Appian Labs, Llc Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2210585A1 (en) 2009-01-16 2010-07-28 Exelgyn SPRM pharmaceutical compositions methods of treatment using them
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10485770B2 (en) 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
EP2554168B1 (en) 2010-03-29 2018-01-24 Astellas Pharma Inc. Controlled release pharmaceutical composition
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013111070A1 (en) 2012-01-23 2013-08-01 Ranbaxy Laboratories Limited In-situ multilayered tablet technology
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN106535878B (zh) 2014-06-02 2022-11-01 科莱西奥生物科技有限公司 可张开的胃内滞留剂型
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
CN113713090B (zh) * 2015-02-09 2023-06-02 安特拉贝欧有限公司 骨质疏松症的治疗
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
US9820957B2 (en) 2016-03-24 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Methods of treating autoimmunity
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3500291A4 (en) 2016-08-17 2020-03-11 Entera Bio Ltd. FORMULA FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
JP7071748B2 (ja) 2016-12-02 2022-05-19 クレキシオ バイオサイエンシーズ エルティーディー． 胃内滞留システム
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
CN111417620B (zh) 2017-12-01 2023-08-25 奥特吉尼克斯制药公司 肌酸前药、其组合物以及使用方法
JP7296084B2 (ja) 2017-12-04 2023-06-22 クレキシオ バイオサイエンシーズ エルティーディー． 長時間作用型胃滞留システム
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
CA3086153A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
IL275312B2 (en) 2017-12-18 2024-09-01 Tris Pharma Inc Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
AU2019269815B2 (en) * 2018-05-15 2024-08-01 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pharmaceutical composition comprising small molecule EGFR inhibitor and preparation method therefor
CN110214860A (zh) * 2019-07-10 2019-09-10 聂刘明 一种宠物饲料及其制备工艺
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
KR20240039030A (ko) * 2021-07-30 2024-03-26 에벡시아 테라퓨틱스 아이엔씨. 5-하이드록시트립토판 위체류성 투여 형태
EP4392031A4 (en) 2021-10-14 2025-07-30 Evecxia Therapeutics Inc METHOD FOR OPTIMIZING 5-HYDROXYTRYPTAMINE FUNCTION IN THE BRAIN FOR THERAPEUTIC PURPOSES
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4839171A (en) * 1984-11-30 1989-06-13 Techmix, Inc. Composition for treating impaired lactation
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
JPH0747534B2 (ja) * 1986-06-02 1995-05-24 ロ−ラ−ジヤパン株式会社 錠 剤
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time

Also Published As

Publication number Publication date
DE69728710D1 (de) 2004-05-27
IT1282650B1 (it) 1998-03-31
CA2197941A1 (en) 1997-08-20
EP1382331A1 (en) 2004-01-21
DK0795324T3 (da) 2004-08-16
AU1477697A (en) 1997-08-28
EP0795324A3 (en) 1998-11-04
PT795324E (pt) 2004-09-30
AU719170B2 (en) 2000-05-04
EP0795324B1 (en) 2004-04-21
ES2376199T3 (es) 2012-03-09
ES2219709T3 (es) 2004-12-01
EP0795324A2 (en) 1997-09-17
NZ314265A (en) 1997-07-27
JP3251190B2 (ja) 2002-01-28
ATE264670T1 (de) 2004-05-15
ATE530173T1 (de) 2011-11-15
ES2376199T8 (es) 2012-04-04
CA2197941C (en) 2001-12-04
JPH09316005A (ja) 1997-12-09
US5780057A (en) 1998-07-14
ITMI960311A1 (it) 1997-08-19
DE69728710T2 (de) 2005-04-07
EP1382331B1 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
ITMI960311A0 (en:Method)
AR026661A2 (en:Method)
BRPI9713914B8 (en:Method)
IN188590B (en:Method)
BR7600721U (en:Method)
BR7601346U (en:Method)
BR9603859A (en:Method)
CN3043413S (en:Method)
CN3044168S (en:Method)
CN3040367S (en:Method)
CN3040543S (en:Method)
CN3040550S (en:Method)
CN3040805S (en:Method)
CN3041115S (en:Method)
CN3041207S (en:Method)
CN3041374S (en:Method)
CN3041383S (en:Method)
CN3042193S (en:Method)
CN3042289S (en:Method)
CN3042424S (en:Method)
CN3042589S (en:Method)
CN3043305S (en:Method)
CN3045880S (en:Method)
CN3043414S (en:Method)
CN3043415S (en:Method)

Legal Events

Date Code Title Description
0001 Granted